Comparative Pharmacology
Head-to-head clinical analysis: METAXALONE versus ROBAXIN 750.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAXALONE versus ROBAXIN 750.
METAXALONE vs ROBAXIN-750
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metaxalone is a centrally acting muscle relaxant whose exact mechanism is unknown. It is thought to produce skeletal muscle relaxation by depressing the central nervous system (CNS), possibly through general CNS depression or by blocking polysynaptic reflexes in the spinal cord.
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
800 mg orally 3 to 4 times daily
750 mg orally four times daily (total daily dose 3000 mg).
None Documented
None Documented
Clinical Note
moderateMetaxalone + Venlafaxine
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine."
Clinical Note
moderateMetaxalone + Nefazodone
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone."
Clinical Note
moderateMetaxalone + Stiripentol
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Stiripentol."
Clinical Note
moderateMetaxalone + Clomipramine
Terminal elimination half-life is approximately 0.5 to 1.5 hours, reflecting rapid clearance and supporting short-lived clinical effects.
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug, with less than 1% eliminated in feces via biliary excretion.
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine."